Snapshot from Sep 15, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory government funding

India PRIP Scheme Second Call

Analysis based on 6 articles · First reported Aug 28, 2026 · Last updated Aug 29, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The second call under the PRIP scheme is expected to boost innovation and R&D investment in India's pharmaceutical and medical technology sectors, potentially benefiting startups and established companies. The government's continued support signals a positive regulatory environment, likely enhancing the competitiveness of Indian pharma and MedTech firms in global markets.

Pharmaceuticals Medical Devices Biotechnology

The India — Ministry of Chemicals and Fertilizers, under the India — Ministry of Chemicals and Fertilizers, announced the second call for applications under the Promotion of Research and Innovation in Pharma & MedTech (PRIP) Scheme. The scheme, with a financial outlay of Rs 5,000 crore, aims to strengthen India's pharma and MedTech R&D ecosystem by supporting startups, MSMEs, and large companies. Financial support of up to Rs 5 crore per project is available for early-stage projects (TRL 1-3) and up to Rs 100 crore per project for later-stage projects (TRL 4-6), subject to a 35% co-funding requirement. The application window opens by mid-September. Priority areas include new medicines, complex generics, biosimilars, and novel medical devices such as AI-based diagnostics and robotic surgical tools. The scheme also provides mentorship and facilitates collaboration through initiatives like MedTech Mitra and Patent Mitra.

govactor
The India — Ministry of Chemicals and Fertilizers is the implementing agency, announcing the second call and managing the application process. This reinforces its role in driving pharma and MedTech innovation in India.
Importance 100.0 Sentiment 40.0
cnt
India is the beneficiary country, with the scheme aimed at strengthening its pharma and MedTech R&D ecosystem. This could enhance India's position as a global hub for pharmaceutical innovation.
Importance 90.0 Sentiment 40.0
curr
The India — Indian rupee is the currency of the scheme's financial outlay and support amounts. The funding injection may have a minor positive effect on the currency's value through increased domestic investment.
Importance 60.0 Sentiment 30.0
govactor
The India — Central Drugs Standard Control Organisation is referenced as the regulatory body for novel medical devices, which are a priority area under the scheme. Its approval processes will be relevant for projects seeking to commercialize innovative devices.
Importance 40.0 Sentiment 20.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.